Nasal fluid release of eotaxin‐3 and eotaxin‐2 in persistent sinonasal eosinophilic inflammation

Corso, Eugenio De; Baroni, Silvia; Battista, Mariapina; Romanello, Matteo; Penitente, Romina; Nardo, Walter Di; Passàli, Giulio Cesare; Sergi, Bruno; Fetoni, Anna Rita; Bussu, Francesco; Zuppi, Cecilia; Paludetti, Gaetano

doi:10.1002/alr.21348

Cited by 35 publications

(46 citation statements)

References 28 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CCL24 (eotaxin 2), CCL11 (eotaxin 1), and CCL26 (eotaxin 3) comprise the main CCR3‐activating chemokines responsible for the recruitment of eosinophils. Eotaxins have been shown to be markedly elevated in nasal polyps . In the present study, we confirmed the upregulation of CCL24 in eosinophilic, but not non‐eosinophilic polyps, and found that CCL24 expression correlated with eosinophilia in nasal polyps.…”

Section: Discussionsupporting

confidence: 85%

Hemokinin‐1 stimulates C‐C motif chemokine ligand 24 production in macrophages to enhance eosinophilic inflammation in nasal polyps

Deng

Wang

et al. 2019

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

Background:The mechanisms underlying mucosal eosinophilia in chronic rhinosinusitis with nasal polyps (CRSwNP) remain poorly clarified. The nervous system and neuropeptides play an important role in the regulation of immune response. Herein we explore the expression and function of hemokinin-1 (HK-1), a newly identified tachykinin, along with its receptor neurokinin 1 receptor (NK1R) in CRSwNP. Methods:HK-1, NK1R, and C-C motif chemokine ligand 24 (CCL24) expression in nasal tissues (53 eosinophilic CRSwNP, 32 non-eosinophilic CRSwNP, and 33 controls) was investigated by quantitative reverse transcript polymerase chain reaction (RT-PCR) and immunofluorescence staining. THP-1, a human monocytic leukemia cell line, and eosinophilic polyp tissues were stimulated with HK-1. Cells, tissues, and culture supernatants were subsequently collected for detection of the production of various inflammatory cytokines and chemokines by quantitative RT-PCR and enzyme-linked immunoassay.Results: HK-1 and NK1R mRNA and protein expression were upregulated in eosinophilic and non-eosinophilic nasal polyps compared with control tissues, with eosinophilic polyps demonstrating a higher upregulation compared with that of non-eosinophilic polyps. Eosinophils constituted the major source of HK-1, whereas macrophages were the predominant cell type exhibiting NK1R in eosinophilic polyps. HK-1 induced CCL24 production from macrophages differentiated from THP-1 cells; this was abolished by an NK1R antagonist. HK-1 also induced CCL24 production from ex vivo-cultured eosinophilic nasal polyps. CCL24 was expressed by macrophages in eosinophilic but not noneosinophilic polyps. The expression level of HK-1 correlated with CCL24 expression and tissue eosinophilia in eosinophilic nasal polyps. Conclusion:Eosinophil-derived HK-1 induces CCL24 production from macrophages and therefore exaggerates eosinophilic inflammation in CRSwNP. C 2019 ARS-AAOA, LLC.

show abstract

Section: Discussionsupporting

confidence: 85%

Hemokinin‐1 stimulates C‐C motif chemokine ligand 24 production in macrophages to enhance eosinophilic inflammation in nasal polyps

Deng

Wang

et al. 2019

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

show abstract

“…Peric et al observed that nasal secretion levels of certain chemokines (MCP‐1, MCP‐3, and RANTES) correlated with nasal symptoms and degree of eosinophilia in patients with NARES and perennial AR. Similarly, we have previously demonstrated an important correlation with the levels of eotaxins and degree of eosinophilia and clinical symptoms in eosinophilic patients . In the present series, we have observed that the levels of eosinophilic biomarkers were modified according to outcomes.…”

Section: Discussionsupporting

confidence: 85%

“…Similarly, we have previously demonstrated an important correlation with the levels of eotaxins and degree of eosinophilia and clinical symptoms in eosinophilic patients. 23,24 In the present series, we have observed that the levels of eosinophilic biomarkers were modified according to outcomes. After treatment, we observed significantly lower levels of eotaxin-1 and eotaxin-2 in responders, whereas an increasing trend was observed in nonresponders, although the difference did not reach statistical significance.…”

Section: Discussionmentioning

confidence: 52%

“…All samples, standards, and controls were assayed in duplicate, and mean values were calculated as in our previous experience. 23,24 The coefficient of variation of duplicates was always less than 7%. The sensitivity of the CCL24 assay was 2.5 pg/mL, and the range was from 2.5 to 2,500 pg/mL.…”

Section: Efficacy Outcomesmentioning

confidence: 94%

“…CCL24 and CCL11 were assayed according to the manufacturer's instructions (R&D Systems, Minneapolis, MN) by Quantikine Human CCL24 and CCL11 Immunoassay ELISA kits designed to measure CCL24 and CCL11 levels in cell culture supernatant, serum, and plasma. All samples, standards, and controls were assayed in duplicate, and mean values were calculated as in our previous experience . The coefficient of variation of duplicates was always less than 7%.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Antileukotrienes improve naso‐ocular symptoms and biomarkers in patients with NARES and asthma

et al. 2018

Self Cite

View full text Add to dashboard Cite

Objective The aim of our study was to analyze the montelukast effectiveness in improving oculonasal symptoms, patient‐reported outcomes (PROs), and eosinophilic biomarkers in patients with nonallergic rhinitis eosinophilic syndrome (NARES). Methods We enrolled prospectively 80 symptomatic patients treated with 10 mg once a day of montelukast in monotherapy for 2 months. All patients were investigated before and after treatment. Nasal symptoms (nasal obstruction, rhinorrhoea, sneezing, nasal itching), ocular symptoms (redness/puffiness, watery eyes), and other PROs (olfactory dysfunction, difficulty going to sleep, nighttime awakenings, and nasal congestion on awakening) were scored by visual analogic scale. The following clinical scores were assessed: Total Nasal Symptom Score (T4NSS), Total Ocular Symptom Score (T2OSS), Total Symptom Score of Patient‐Reported Outcomes (TSS‐PROs), and a Composite Symptoms Score (CSS). Patients were classified as responders when a reduction of at least 50% of the CSS was observed. Before and after treatment, the eosinophilic biomarkers in nasal lavage were analyzed: nasal eosinophilia (number of eosinophils per high power field), eotaxin‐1 and eotaxin‐2. Results After treatment, significant reductions were observed for all the symptom scores. Forty‐two of 78 patients were considered responders. A significant reduction of eosinophils in nasal mucosa and of levels of eotaxin‐1 and eotaxin‐2 in nasal lavage were observed after treatment in responder patients. Patients with asthma had an increased probability to be responders. Conclusion NARES patients may benefit from treatment with montelukast. In particular, the presence of concomitant asthma may be predictive of a greater efficacy. Level of Evidence 2 Laryngoscope, 129:551–557, 2019

show abstract

Editorial

Kennedy¹

2014

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

Nasal fluid release of eotaxin‐3 and eotaxin‐2 in persistent sinonasal eosinophilic inflammation

Cited by 35 publications

References 28 publications

Hemokinin‐1 stimulates C‐C motif chemokine ligand 24 production in macrophages to enhance eosinophilic inflammation in nasal polyps

Hemokinin‐1 stimulates C‐C motif chemokine ligand 24 production in macrophages to enhance eosinophilic inflammation in nasal polyps

Antileukotrienes improve naso‐ocular symptoms and biomarkers in patients with NARES and asthma

Editorial

Contact Info

Product

Resources

About